Tenofovir Disoproxil Fumarate in the Treatment of Parkinson's Disease

Recruiting now · Phase 1 · Has a placebo group

Conditions studied: Parkinson Disease

In brief

To evaluate the efficacy and safety of tenofovir disoproxil fumarate in the treatment of Parkinson's disease. The changes of motor symptoms and the occurrence of adverse reactions in early Parkinson's disease patients who took tenofovir disoproxil fumarate and did not take Tenofovir disoproxil fumarate at different time points were compared.

Key facts

Study ID

NCT06356662

Run by

The Fourth Affiliated Hospital of Zhejiang University School of Medicine

People needed

60

Starts

2024-01-23

Expected to finish

2025-12-31

Last updated by the study team

2025-02-17

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• 1: Parkinson's disease: Hoehn Yahr= 1 to 2.5 2: MMSE score≥24

You may not qualify if…

• 1: essential tremor, stroke, epilepsy and other well-defined neurological disorders
• 2: Or have received deep brain stimulation and other brain surgery
• 3: Abnormal liver and kidney function
• 4: Infected with chronic hepatitis B or AIDS (HIV-1 infection)
• 5: Severe depression, schizophrenia, other psychiatric disorders or drug dependence
• 6: Other serious physical diseases such as heart, lung, liver, kidney disease, blood disease and malignant tumor
• 7: Pregnant or lactating women and seniors over 65 years of age
• 8: Allergy or other contraindications to the investigational drug

Where it is running

• Guohua Zhao — Hangzhou, Zhejiang, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.